HYPER-CVAD regimen: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[Doxorubicin| | {{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[Doxorubicin|doxorubicin (Adriamycin)]], and [[dexamethasone]] used to treat some forms of [[leukemia]], [[non-Hodgkin's lymphoma]], [[lymphoblastic lymphoma]] , and [[multiple myeloma]].<ref name="pmid22058209">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al.| title=Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. | journal=Haematologica | year= 2012 | volume= 97 | issue= 3 | pages= 442-50 | pmid=22058209 | doi=10.3324/haematol.2011.043372 | pmc=PMC3291601 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058209 }} </ref> | ||
==Regimen== | ==Regimen== | ||
Revision as of 16:46, 31 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen
Overview
HYPER-CVAD regimen refers to a regimen consisting of cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of leukemia, non-Hodgkin's lymphoma, lymphoblastic lymphoma , and multiple myeloma.[1]
Regimen
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin, Hydroxydaunorubicin)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N; et al. (2012). "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results". Haematologica. 97 (3): 442–50. doi:10.3324/haematol.2011.043372. PMC 3291601. PMID 22058209.